Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Search

Total 116 results found. Search for [ sun pharmaceuticals ]

Results 1-20 of 116
By Tanvi verma
Delhi, Edition:May 7, 2017

Making the most of a share buyback offer largely dependson the winning combination of premium pricing and high acceptance ratio

By Joe C. Mathew
Delhi, Edition:April 9, 2017

In spite of favourable court verdicts, top pharmaceutical companies are losing enthusiasm for fixed dose combination medicines.

BT Online
March 7, 2017
Twenty one billionaires in the Hurun Global Rich List India are from pharmaceuticals sector.
PTI
February 15, 2017
The benchmark Sensex extended losses for second straight day, plummeting 183.75 points to close 28,155.56, while the broader Nifty dropped well-below the crucial 8,800-level following sustained sell-off across the sectors despite firm global cues.
E Kumar Sharma
New Delhi, January 18, 2017
Its misadventure in India had began in June 2008 with the acquisition of Ranbaxy in an over $4-billion deal (around Rs 20,000 crore then) with the promise of utilising Ranbaxy's resources to become a 'global pharma innovator'.
by P.B. Jayakumar
Delhi, Edition:January 1, 2017

Torrent Pharmaceuticals was a late entrant to the US, but Samir Mehta has led it to fast-paced growth in that market.

By Prosenjit Datta
Delhi, Edition:October 23, 2016
The Indian pharmaceutical industry has spawned many fascinating stories of entrepreneurs, who started out with limited or no resources but went on to build multinational operations and highly profitable companies, seizing opportunities in India and abroad as they came along.
E Kumar Sharma
Edition:July 17, 2016
Today, the research centre in Gurgaon remains the last remnant, in terms of a direct physical presence and arguably a positive highlight, of around $10-billion (986.4 billion yen) Japanese pharma major's misadventure in India.
IANS
June 8, 2016
Members of the US-India Business Council have already invested $28 billion in India since September 2014 and another $45 billion is in the pipeline, Council Chairman John Chambers told Prime Minister Narendra Modi here.
Joe C Mathew
May 6, 2016
Breach of faith, dreams turned sour and a $5.35 billion hole in the pocket. That, in substance, was the Japanese pharma major Daiichi-Sankyo's failed India sojourn that began in June, 2008 and packed up in April, 2014.
PTI
Washington, May 6, 2016
Modi's address to the US-India Business Council (USIBC) before who's who of American corporate sector would be on June 7. He will also participate in a roundtable with leading global CEOs.
By E. Kumar Sharma
Delhi, Edition:May 8, 2016
In the third quarter, Dr. Reddy's revenues from India rose 34 per cent from the corresponding quarter of the previous year (partly due to acquisition of a few established brands of Belgian company UCB in India). However, in March, the growth was 7 per cent.
BT Online
New Delhi, February 4, 2016
Shares of Pfizer India, world's premier biopharmaceutical firm, surged over 5 per cent after the company reported a two-fold year-on-year jump in Q3 profits at Rs 40.34 crore.
BT Online
New Delhi, February 4, 2016
The stock fell on news report that the US government has made it mandatory for Active Pharmaceutical Ingredients (APIs) to be manufactured locally.
PTI
New Delhi, October 28, 2015
Market experts said that a slew of global and domestic factors including concerns over economic slowdown in China and weak GDP numbers in India prompted FIIs to reduce their holdings.
BT Online Bureau
New Delhi, August 12, 2015
With the impasse in Parliament over the GST Bill and yuan devaluation here are the five stocks that remained in news today.
BT Online Bureau
Mumbai, August 12, 2015
"For Q1 FY16, Sun Pharmaceuticals posted results better than expected, on sales front," said Sarabjit Kour Nangra (VP Research - Pharma), Angel Broking.
E Kumar Sharma
July 28, 2015
Following the completion of the acquisition, a company statement said Teva "is expected to have pro forma sales of approximately $26 billion and EBITDA of approximately $9.5 billion in 2016, including an estimated $11 billion in sales outside of the United States."
E Kumar Sharma
June 1, 2015
These are tricky times for Indian pharma and they can hardly afford any lapse in their production facilities when the US drug regulator (the US Food and Drug Administration) inspections happen.
BT Online Bureau
June 1, 2015
The share price of Sun Pharma tanked 9 per cent to Rs 878.95 after the announcement of lower-than-expected fourth quarter result.
PAGES 1 OF 6  12345
 By Stories    By Author  
From (yyyy-mm-dd)